A novel phase 1 trial explores the safety and efficacy of targeted radiotherapy for leptomeningeal metastases in breast cancer patients.
Andrew Brenner, MD, PhD
Advertisement
Andrew Brenner, MD, PhD, is a breast and neuro-oncology specialist and professor of medicine in the Division of Hematology and Oncology at the University of Texas Health Science Center at San Antonio.
Articles by Andrew Brenner, MD, PhD
Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated strong safety in patients with leptomeningeal metastases.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
3
FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies
4
Aficamten Outperforms Metoprolol Across All Phases of Exercise in Obstructive HCM
5